Advertisement Royal Philips, University of California team up on breast cancer screening technology - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Royal Philips, University of California team up on breast cancer screening technology

Royal Philips has joined forces with the University of California, Irvine, in a bid to develop standards for breast cancer screening.

The companies will conduct a study assess the clinical accuracy of spectral imaging technology with low radiation dose to measure breast density, potentially increasing accuracy of cancer detection and arming patients with better tools for care.

The study will be based on the Dutch company’s MicroDose SI mammography spectral imaging technology, which has been designed to address the industry’s concern about the lower diagnostic accuracy of mammography for high density breasts.

Royal Philips Imaging CEO Gene Saragnese said: "Through this study, UC Irvine and Philips are looking to set an industry standard for objectively measuring breast density.

"With the combination of our MicroDose SI technology and leading imaging experts at UC Irvine, we can determine if spectral breast imaging can help provide more definitive diagnoses, at low radiation dose, to better help patients and clinicians in the fight against breast cancer."

University of California, Irvine School of Medicine professor of radiological sciences Sabee Molloi said: "Leveraging Philips’ spectral imaging technology, this study will help us validate breast density measurements and set industry standards, which can help enhance the quality of diagnoses and treatment."

As part of the study’s initial phase, the accuracy of the spectral breast density application would be assessed by analyzing 40 post-mortem breasts and comparing results with chemical analysis.

The study is slated for completion over a one- to two-year-long period.